Wall Street Zen Upgrades Hims & Hers Health (NYSE:HIMS) to "Buy"

Hims & Hers Health (NYSE:HIMS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Sunday.

A number of other research firms also recently commented on HIMS. Bank of America lifted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. Citigroup reaffirmed a "sell" rating and set a $30.00 target price (up previously from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Piper Sandler reiterated a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, Truist Financial cut their price objective on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Hold" and a consensus price target of $38.00.

Hims & Hers Health Stock Performance

HIMS stock opened at $55.33 on Friday. Hims & Hers Health has a one year low of $13.47 and a one year high of $72.98. The company's 50 day moving average price is $45.09 and its two-hundred day moving average price is $38.21. The company has a market capitalization of $12.38 billion, a PE ratio of 125.75 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health's revenue was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.05 EPS. On average, research analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the transaction, the insider now owns 8,007 shares in the company, valued at $230,441.46. The trade was a 21.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael Chi sold 5,600 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $57.00, for a total value of $319,200.00. Following the sale, the insider now owns 256,380 shares in the company, valued at $14,613,660. The trade was a 2.14% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 628,067 shares of company stock valued at $25,832,688 over the last quarter. Company insiders own 13.71% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter valued at $30,000. Smartleaf Asset Management LLC lifted its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter worth $38,000. Finally, UMB Bank n.a. increased its stake in shares of Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after acquiring an additional 933 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.